Effect of ursobil on neonatal bilirubi
Phase 3
Recruiting
- Conditions
- eonatal hyperbilirubinemia.neonatal jundice, unspecified
- Registration Number
- IRCT20181003041225N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Body weight 2500-4000 gram
Exclusive breast feeding
Gestational age 38-41 weeks
Total bilirubin 14-20
Direct bilirubin less than 2
Exclusion Criteria
ABO or Rh incompatibility
Neonatal G6PD deficiency
Sepsis symptoms
Thyroid dysfunction
Liver diseases
Prematurity
Maternal diabetes
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of the patients receiving unconjugated bilirubin 12, within 24 hours of admission. Timepoint: Unconjugated bilirubin level at the beginning of the study and every 12 hours to reach bilirubin 12. Method of measurement: Serum bilirubin.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: Time interval of admission to discharge. Method of measurement: Checking hours of hospitalization.;Different side effects like diarrhea, vomiting, skin rash. Timepoint: Time interval of admission to 1 week after discharge. Method of measurement: History and physical exam.;Determining the percentage of patients receiving bilirubin 12, after 24 hours and before 48 hours of admission. Timepoint: 24 and 48 hours after being admitted. Method of measurement: Serum bilirubin.